IP Library Granted Patent US 8,889,868
Granted Patent B2
US 8,889,868 · App. 13/126,920 · Granted Nov 18, 2014

CC-1065 analogs and their conjugates

Inventors: Patrick Henry Beusker (Nijmegen, NL); Rudy Gerardus Elisabeth Coumans (Nijmegen, NL); Ronald Christiaan Elgersma (Nijmegen, NL); Wiro Michaël Petrus Bernardus Menge (Nijmegen, NL); Johannes Albertus Frederikus Joosten (Nijmegen, NL); Henri Johannes Spijker (Nijmegen, NL); Franciscus Marinus Hendrikus de Groot (Nijmegen, NL)
Assignee: Syntarga BV
C07D403/14C07D491/048A61K31/4355A61K31/437C07D403/06C07D413/06C07D417/06C07D471/04C07D495/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,889,868
App. No.
13/126,920
Granted
Nov 18, 2014
Kind
B2
Abstract

This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

Claims (31)

1. A compound of formula (I) or (II):

or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein R 1 is a leaving group;

R 2 , R 2′ , R 3 , R 3′ , R 4 , R 4′ , R 12 , and R 19 are independently selected from H, OH, SH, NH 2 , N 3 , NO 2 , NO, CF 3 , CN, C(O)NH 2 , C(O)H, C(O)OH, halogen, R a , SR a , S(O)R a , S(O) 2 R a , S(O)OR a , S(O) 2 OR a , OS(O)R a , OS(O) 2 R a , OS(O)OR a , OS(O) 2 OR a , OR a , NHR a , N(R a )R b , + N(R a )(R b )R c , P(O)(OR a )(OR b ), OP(O)(OR a )(OR b ), SiR a R b R c , C(O)R a , C(O)OR a , C(O)N(R a )R b , OC(O)R a , OC(O)OR a , OC(O)N(R a )R b , N(R a )C(O)R b , N(R a )C(O)OR b , and N(R a )C(O)N(R b )R c , wherein

R a , R b , and R c are independently selected from H and optionally substituted C 1-3 alkyl or C 1-3 heteroalkyl,

or R 3 +R 3′ and/or R 4 +R 4′ are independently selected from ═O, ═S, ═NOR 18 , ═C(R 18 )R 18′ , and ═NR 18 , R 18 and R 18′ being independently selected from H and optionally substituted C 1-3 alkyl, two or more of R 2 , R 2′ , R 3 , R 3′ , R 4 , R 4′ , and R 12 optionally being joined by one or more bonds to form one or more optionally substituted carbocycles and/or heterocycles;

X 2 is selected from O, C(R 14 )(R 14′ ), and NR 14′ , wherein R 14 and R 14′ have the same meaning as defined for R 7 and are independently selected, or R 14′ and R 7′ are absent resulting in a double bond between the atoms designated to bear R 7′ and R 14′ ;

R 5 , R 5′ , R 6 , R 6′ , R 7 , and R 7′ are independently selected from H, OH, SH, NH 2 , N 3 , NO 2 , NO, CF 3 , CN, C(O)NH 2 , C(O)H, C(O)OH, halogen, R e , SR e , S(O)R e , S(O) 2 R e , S(O)OR e , S(O) 2 OR e , OS(O)R e , OS(O) 2 R e , OS(O)OR e , OS(O) 2 OR e , OR e , NHR e , N(R e )R f , + N(R e )(R f )R g , P(O)(OR e )(OR f ), OP(O)(OR e )(OR f ), SiR e R f R g , C(O)R e , C(O)OR e , C(O)N(R e )R f , OC(O)R e , OC(O)OR e , OC(O)N(R e )R f , N(R e )C(O)R f , N(R e )C(O)OR f , N(R e )C(O)N(R f )R g , and a water-soluble group, wherein

R e , R f , and R g are independently selected from H and optionally substituted (CH 2 CH 2 O) ee CH 2 CH 2 X 13 R e1 , C 1-15 alkyl, C 1-15 heteroalkyl, C 3-15 cycloalkyl, C 1 - 15 heterocycloalkyl, C 5-15 aryl, or C 1-15 heteroaryl, wherein ee is selected from 1 to 1000, X 13 is selected from O, S, and NR f1 , and R f1 and R e1 are independently selected from H and C 1-3 alkyl, one or more of the optional substituents in R e , R f , and/or R g optionally being a water-soluble group, two or more of R e , R f , and R g optionally being joined by one or more bonds to form one or more optionally substituted carbocycles and/or heterocycles,

or R 5 +R 5′ and/or R 6 +R 6′ and/or R 7 +R 7′ are independently selected from ═O, ═S, ═NOR e3 , ═C(R e3 )R e4 , and ═NR e3 , R e3 and R e4 being independently selected from H and optionally substituted C 1-3 alkyl, or R 5′ +R 6′ and/or R 6′ +R 7′ and/or R 7′ +R 14′ are absent, resulting in a double bond between the atoms designated to bear R 5′ and R 6′ , and/or R 6′ and R 7′ , and/or R 7′ and R 14′ , respectively, two or more of R 5 , R 5′ , R 6 , R 6′ , R 7 , R 7′ , R 14 , and R 14′ optionally being joined by one or more bonds to form one or more optionally substituted carbocycles and/or heterocycles;

X 1 is selected from O, S, and NR 13 , wherein R 13 is selected from H and optionally substituted C 1-8 alkyl or C 1-8 heteroalkyl and not joined with any other substituent;

wherein DB is selected from the group consisting of:

R 8 , R 9 , R 10 , R 11 , R 15 , and R 16 are each independently selected from H, OH, SH, NH 2 , N 3 , NO 2 , NO, CF 3 , CN, C(O)NH 2 , C(O)H, C(O)OH, halogen, R h , SR h , S(O)R h , S(O) 2 R h , S(O)OR h , S(O) 2 OR h , OS(O)R h , OS(O) 2 R h , OS(O)OR h , OS(O) 2 OR h , OR h , NHR h , N(R h )R i , + N(R h )(R i )R j , P(O)(OR h )(OR i ), OP(O)(OR h )(OR i ), SiR h R i R j , C(O)R h , C(O)OR h , C(O)N(R h )R i , OC(O)R h , OC(O)OR h , OC(O)N(R h )R i , N(R h )C(O)R i , N(R h )C(O)OR i , N(R h )C(O)N(R i )R j , and a water-soluble group, wherein

R h , R i , and R j are independently selected from H and optionally substituted (CH 2 CH 2 O) ee CH 2 CH 2 X 13 R e1 , C 1-15 alkyl, C 1-15 heteroalkyl, C 3-15 cycloalkyl, C 1-15 heterocycloalkyl, C 5-15 aryl, or C 1-15 heteroaryl, one or more of the optional substituents in R h , R i , and/or R j optionally being a water-soluble group, two or more of R h , R i , and R j optionally being joined by one or more bonds to form one or more optionally substituted carbocycles and/or heterocycles,

one of R 2 , R 2′ , R 3 , and R 3′ and one of R 5 and R 5′ may optionally be joined by one or more bonds to form one or more optionally substituted carbocycles and/or heterocycles;

a and b are independently selected from 0 and 1;

wherein for each group that is optionally substituted, the substituent, when present, is selected from the group consisting of OH, ═O, ═S, ═NR k , ═N—OR k , SH, NH 2 , NO 2 , NO, N 3 , CF 3 , CN, OCN, SCN, NCO, NCS, C(O)NH 2 , C(O)H, C(O)OH, halogen, R k , SR k , S(O)R k , S(O)OR k , S(O) 2 R k , S(O) 2 OR k , OS(O)R k , OS(O)OR k , OS(O) 2 R k , OS(O) 2 OR k , S(O)N(R k )R l , OS(O)N(R k )R l , S(O) 2 N(R k )R l , OS(O) 2 N(R k )R l , OP(O)(OR k )(OR l ), P(O)(OR k )(OR l ), OR k , NHR k , N(R k )R l , + N(R k )(R l )R m , Si(R k )(R l )(R m ), C(O)R k , C(O)OR k , C(O)N(R k )R l , OC(O)R k , OC(O)OR k , OC(O)N(R k )R l , N(R k )C(O)R l , N(R k )C(O)OR l , N(R k )C(O)N(R l )R m , a water-soluble group, and the thio derivatives of these substituents, and protonated, charged, and deprotonated forms of any of these substituents, wherein R k , R l , and R m are independently selected from H and optionally substituted —(CH 2 CH 2 O) yy CH 2 CH 2 X 17 R yy , C 1-15 alkyl, C 1-15 heteroalkyl, C 3-15 cycloalkyl, C 1-15 heterocycloalkyl, C 5-15 aryl, or C 1-15 heteroaryl, or a combination thereof, wherein yy is selected from 1 to 1000, X 17 is independently selected from O, S, and NR zz , and R zz and R yy are independently selected from H and C 1-3 alkyl, two or more of R k , R l , and R m optionally being joined by one or more bonds to form one or more optionally substituted carbocycles and/or heterocycles; and

wherein the water-soluble group is selected from the group consisting of polyalcohols, straight chain or cyclic saccharides, primary, secondary, tertiary, or quaternary amines and polyamines, sulfate groups, sulfonate groups, sulfinate groups, carboxylate groups, phosphate groups, phosphonate groups, phosphinate groups, ascorbate groups, glycols, and polyethers.

2. The compound according to claim 1 wherein DB is selected from

3. The compound according to claim 1 which is a compound of the formula

4. The compound according to claim 1 wherein R 5 is selected from methyl, ethyl, propyl, isopropyl, nitro, CF 3 , F, Cl, Br, cyano, methoxy, ethoxy, propoxy, isopropoxy, amino (NH 2 ), methylamino, formyl, hydroxymethyl, and dimethylamino.

5. The compound according to claim 1 wherein at least one of the substituents R 1 , R 5 , R 5′ , R 6 , R 6′ , R 7 , R 7′ , R 14 , R 14′ , R 8 , R 9 , R 10 , R 11 , R 15 , and R 16 contains a X 14 (CH 2 CH 2 O) ff CH 2 CH 2 X 14 moiety, wherein ff is selected from 1 to 1000 and each X 14 is independently selected from

that is connected to the attachment site of said substituent either via a direct bond or via a moiety, being part of said same substituent, that does not comprise a disulfide, a hydrazone, a hydrazide, an ester, a natural amino acid, or a peptide containing at least one natural amino acid.

6. The compound according to claim 1 wherein at least one of the substituents R 1 , R 5 , R 5′ , R 6 , R 6′ , R 7 , R 7′ , R 14 , R 14′ , R 8 , R 9 , R 10 , R 11 , R 15 , and R 16 contains a triazole moiety.

7. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

8. The compound according to claim 1 wherein DB is

9. The compound according to claim 3 , wherein DB is selected from

10. The compound according to claim 9 wherein DB is

11. The compound according to claim 3 wherein R 5 is selected from methyl, ethyl, propyl, isopropyl, nitro, CF 3 , F, Cl, Br, cyano, methoxy, ethoxy, propoxy, isopropoxy, amino (NH 2 ), methylamino, formyl, hydroxymethyl, and dimethylamino.

12. The compound according to claim 9 wherein the compound is selected from the group consisting of the compounds of formula 71, 72, 73, 74, 75, 76, and 77:

13. The compound according to claim 9 wherein the compound is selected from the group consisting of the compounds of formula 58, 59, 60, and 61:

14. The compound according to claim 10 wherein the compound is selected from the group consisting of the compounds of formula 81, 84, 85, and 86:

Assignments (2)
MERGER Recorded Feb 9, 2023
From: SYNTARGA B.V.
To: BYONDIS B.V.
Reel/Frame 062642/0970 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2011
From: BEUSKER, PATRICK HENRY; COUMANS, RUDY GERARDUS ELISABETH; ELGERSMA, RONALD CHRISTIAN; MENGE, WIRO MICHAEL PETRUS BERNARDUS; JOOSTEN, JOHANNES ALBERTUS FREDERKUS; SPIJKER, HENRI JOHANNES; DE GROOT, FRANCISCUS MARINUS HENDRIKUS
To: SYNTARGA B.V.
Reel/Frame 026340/0773 →
Continuity (4)
Provisional Application 61110765 · Nov 3, 2008
Provisional Application 61140213 · Dec 23, 2008
Provisional Application 61170231 · Apr 17, 2009
Related Publication 20110207767A1 · Aug 25, 2011